脾多肽注射液与R-CHOP方案在弥漫大B细胞淋巴瘤中的疗效及对机体免疫功能、VEGF、bFGF水平的影响分析  

Efficacy of Spleen Polypeptide Injection and R-CHOP Regimen in Diffuse Large B-cell Lymphoma and Their Effects on Immune Function,VEGF and bFGF Levels

作　　者：张倩 颜宗海 ZHANG Qian;YAN Zonghai(Department of Internal Medicine,Liangzhu Hospital,Yuhang District,Hangzhou,Zhejiang Province,311100 China;Department of Hematology,Chaohu Hospital Affiliated to Anhui Medical University,Hefei,Anhui Province,238000 China)

机构地区：[1]杭州市余杭区良渚医院内科,浙江杭州311100 [2]安徽医科大学附属巢湖医院血液内科,安徽合肥238000

出　　处：《系统医学》2022年第9期23-26,31,共5页Systems Medicine

摘　　要：目的探讨脾多肽注射液联合R-CHOP化疗方案治疗弥漫大B淋巴细胞瘤(DLBCL)的效果及对患者免疫功能、血管内皮生长因子(VEGF)、碱性成纤维细胞生长因子(bFGF)水平的影响。方法选取2019年10月—2021年10月期间杭州市余杭区良渚医院收治的84例DLBCL患者作为研究对象,采用随机数字表法将其分为研究组和对照组,每组42例,两组患者均统一接受弥漫大B细胞淋巴瘤R-CHOP化疗方案治疗,研究组在此基础上采用脾多肽注射液配合治疗,比较两组患者实施治疗3个月后的客观缓解率(ORR)、疾病控制率(DCR)、总生存期(OS),治疗前后的免疫因子(CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))水平及血清相关指标(VEGF、bFGF)的变化情况,统计两组患者的并发症发生情况。结果研究组治疗3个月后的ORR、DCR、OS均高于对照组。治疗后的CD3^(+)、CD4^(+)、CD8^(+)低于对照组,CD_(4)^(+)/CD_(8)^(+)高于对照组,VEGF、bFGF低于对照组,差异有统计学意义(P<0.05)。治疗后研究组并发症发生率14.28%(6/42)低于对照组35.71%(15/42),差异有统计学意义(χ^(2)=5.143,P=0.023)。结论对DLBCL患者实施R-CHOP化疗方案治疗同时采用脾多肽注射液配合治疗对提高患者近期疗效、促进免疫功能、抑制新生血管增长均有着积极作用,此联合方案可降低患者并发症发生风险,具有较高的临床推广价值。Objective To investigate the effect of spleen polypeptide injection combined with R-CHOP chemotherapy regimen in the treatment of diffuse large B lymphocyte tumor(DLBCL)and its effects on immune function,vascular endothelial growth factor(VEGF),basic fibroblast growth factor(bFGF)level effect.Methods A total of 84 DLBCL patients admitted to Liangzhu Hospital in Yuhang District,Hangzhou from October 2019 to October 2021 were selected as the research subjects.They were divided into study group and control group by random number table method,42 cases in each group.Both groups of patients were uniformly treated with R-CHOP chemotherapy regimen for diffuse large B-cell lymphoma,and the study group was treated with spleen polypeptide injection on this basis.The objective response rate(ORR),disease control rate(DCR),overall survival(OS),and levels of immune factors(CD_(3)^(+),CD_(4)^(+),CD_(8)^(+),CD_(4)^(+)/CD_(8)^(+))before and after treatment were compared between the two groups of patients after 3 months of treatment.Changes of serum related indexes(VEGF,bFGF).The incidence of complications in the two groups of patients was counted.Results After 3 months of treatment,the ORR,DCR and OS of the study group were higher than those of the control group.After treatment,CD_(3)^(+),CD_(4)^(+),CD_(8)^(+) were lower than those in the control group,and CD_(4)^(+)/CD_(8)^(+) was higher than that in the control group,VEGF and bFGF were lower than those in the control group,the difference was statistically significant(P<0.05).After treatment,the incidence of complications in the study group was 14.28%(6/42)lower than 35.71%(15/42)in the control group,the difference was statistically significant(χ^(2)=5.143,P=0.023).Conclusion The R-CHOP chemotherapy regimen combined with spleen polypeptide injection for DLBCL patients has positive effects on improving the short-term curative effect,promoting immune function and inhibiting the growth of new blood vessels.This combined regimen can reduce the risk of complications in patients and h

关 键 词：弥漫大B细胞淋巴瘤 R-CHOP化疗 脾多肽注射液 免疫功能 血管内皮生长因子 碱性成纤维生长因子 影响分析 

分 类 号：R4[医药卫生—临床医学]